Using acquired knowledge and new technologies in alcoholism treatment trials.
This article represents the proceedings of a symposium held at the 2001 RSA meeting in Montreal, Canada. The organizer and chair was Barbara A. Flannery and the discussant was Raye Z. Litten. The presentations were (1) The use of biomarkers in alcohol-dependence treatment trials, by John P. Allen; (2) Strategies for enhancing patient compliance in clinical treatment trials, by Helen M. Pettinati; (3) The predictive utility of an alcohol-craving measure, by Barbara A. Flannery; (4) What should be the primary outcome measures in a clinical trial, by Damaris J. Rohsenow; (5) Innovative strategies for assessing functional outcomes in alcoholism treatment clinical trials, by Ron A. Cisler.
Flannery
Barbara A
BA
Center for Interdisciplinary Substance Abuse Research, RTI International, PO Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709-2194, USA. bflannery@rti.org
Allen
John P
JP
Pettinati
Helen M
HM
Rohsenow
Damaris J
DJ
Cisler
Ron A
RA
Litten
Raye Z
RZ
D000437:Alcoholism / Q000628:therapy*; D015415:Biomarkers / Q000032:analysis; D002986:Clinical Trials as Topic / Q000379:methods* / Q000706:statistics & numerical data; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data
D015415:Biomarkers